A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)

🧪 Interventions in This Study

• INCB161734 (DRUG)
• Cetuximab (DRUG)
• Retifanlimab (DRUG)
• GEMNabP (DRUG)
• mFOLFIRINOX (DRUG)
• FOLFOX (DRUG)
• FOLFIRI (DRUG)
• INCA33890 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (34 Sites)

Showing the first 25 of 34 sites.

• Mayo Clinic Hospital — Phoenix, Arizona
• Stanford University — Palo Alto, California
• UCLA Healthcare Hematology-Oncology — Santa Monica, California
• Sarah Cannon Research Institue At Healthone — Denver, Colorado
• Florida Cancer Specialists — Sarasota, Florida
• Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins — Baltimore, Maryland
• Dana Farber Cancer Institute — Boston, Massachusetts
• Hackensack University Medical Center — Hackensack, New Jersey
• Weill Cornell Medicine — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Jefferson University Hospitals — Philadelphia, Pennsylvania
• Scri Oncology Partners — Nashville, Tennessee
• Md Anderson Cancer Center — Houston, Texas
• Chris Obrien Lifehouse — Camperdown, New South Wales
• St Vincent'S Hospital Sydney — Darlinghurst, New South Wales
• Peter Maccallum Cancer Centre — Melbourne, Victoria
• The Alfred Hospital — Melbourne, Victoria
• Linear Clinical Research — Nedlands, Western Australia
• Cliniques Universitaires Ucl Saint-Luc — Brussels,
• Universitair Ziekenhuis Antwerpen (Uza) — Edegem,
• Universitair Ziekenhuis (Uz) Leuven — Leuven,
• The Ottawa Hospital Cancer Center — Ottawa, Ontario
• Princess Margaret Cancer Center — Toronto, Ontario
• Centre Leon Berard — Lyon,
• Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole — Toulouse,

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.